pharmacy-biopharma-2017-posters-accepted-abstracts

Page 55

conferenceseries

.com

Volume 9, Issue 5 (Suppl)

J Bioequiv Availab, an open access journal

ISSN: 0975-0851

Pharmacy & Biopharma 2017

August 31-September 01, 2017 Philadelphia, USA

August 31-September 01, 2017 Philadelphia, USA

International Conference on

Biopharmaceutics and Biologic Drugs

International Pharmacy Conference

J Bioequiv Availab 2017, 9:5 (Suppl)

DOI: 10.4172/0975-0851-C1-031

Synthesis and biological activity evaluation of 2-(5-substituted1-((piperazino) methyl)-2-oxoindolin-3-

ylidene) N-substituted-hydrazinecarbothioamides

Amol Kulkarni

Siddhant College of Pharmacy, India

arious 5-substituted-2-(1-((piperazino) methyl) 2-oxoindolin-3-ylidene) hydrazine carbothioamide and 5-substituted-2-

(1-((piperazino) methyl)-2-oxoindolin3-ylidene)-N-(phenyl-4-substituted) hydrazine carbothioamide derivatives were

synthesized. The compounds were screened for cytotoxicity against human HeLa and CEM T-lymphocytes as well as murine

L1210 cells. Several of these compounds were endowed with low micromolar 50% cytostatic concentration (IC50) values, and

some were virtually equally potent as melphalan. The most potent inhibitors against the murine leukemia cells (L1210) were

also the most inhibitory against human T-lymphocyte (CEM) tumor cells. Derivative 2-(1-((piperazino) methyl)-2-oxoindolin-

3-ylidene)-N-(4 methoxyphenyl)hydrazinecarbothioamide 5c emerged as the most potent cytostatic compound among the

tested compounds. All derivatives showed antiviral activity against HeLa cell cultures (IC50 11–20 lM). The encouraging

cytostatic and antiviral activity data provides an adequate rationale for further modification of these molecular scaffolds.